report by BlackRock
Results for ""
Policy and Regulatory Commentary
Anatomy of a Recession: The Fed's Job Problem
This piece is approved to use with clients.
A review of the United States economy with focus on the Federal Reserve, labor, and housing with Jeff Schulze, investment strategist at ClearBridge Investments.
Sustainable Investing
Global Perspectives: Sustainable Investing in Clean Technologies
This piece is approved to use with clients.
In this episode of our “Global Perspectives” podcast series, Global Sustainable Equity Portfolio Managers Hamish Chamberlayne and Aaron Scully join Adam Hetts to discuss the latest trends in sustainability.
Sustainable Investing
International Women’s Day: Women at the heart of the COVID-19 recovery
This piece is approved to use with clients.
We celebrate this year’s International Women’s Day whilst at a critical juncture for global gender equality.Although recent years have seen progress on, for example, female presentation in leadership positions, the Covid-19 pandemic has laid bare and deepened already existing inequities
Sustainable Investing
ESG in 2021: Closing the Expectations Gap
This piece is approved to use with clients.
Antony Marsden, Head of Governance and Responsible Investment, explores key themes related to Environmental, Social and Governance (ESG) investing in 2021, including why a rethink on ratings is necessary to align expectations with reality.
Sustainable Investing
Global Sustainable Equity: News and Opportunities
This piece is approved to use with clients.
Reflecting on the last quarter of 2020 and looking ahead to the opportunities in the world of sustainability.
Sustainable Investing
Influencing for good: 20 years of engagement
This piece is approved to use with clients.
The way investors conduct engagement has transformed. From a niche approach largely confined to mission-orientated investors, engagement is now a mainstream investor activity. The success of the Climate Action 100+ initiative in bringing together investors, representing close to US$40 trillion in assets, shows how far we have come.
Sustainable Investing
ESG Viewpoint – COVID-19 and the pharmaceutical industry
This piece is approved to use with clients.
Public trust in the pharmaceutical industry has eroded. The pandemic provides drug-makers a chance to begin re-building their reputation – but only if they prioritise socially responsible practices.